Elena Vezzoli

Elena Vezzoli

Auto-generated profile, based on publicly available information

Elena Vezzoli

ALEMBIC Advanced Light and Electron Microscopy Experimental Imaging Center, IRCCS San Raffaele Scientific Hospital, Milan, Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2021 in Science
Verified
Journal Article
Closed access
PDF file
VBVittoria Dickinson Bocchi
Vittoria Dickinson Bocchi
PCPaola Conforti
Paola Conforti
EVElena Vezzoli
Elena Vezzoli
DBDario Besusso
Dario Besusso
CCClaudio Cappadona
Claudio Cappadona
ECElena Cattaneo
Elena Cattaneo
Development of the human striatum revealed: Deep in the brain, the striatum receives and coordinates inputs from other parts of the brain. Bocchi et al. surveyed molecular features as the striatum develops in the human brain. Single-cell surveys of long intergenic noncoding RNAs revealed a progenitor for medium spiny neurons and provide insight into evolutionary divergence of this critical part of the brain. Science , this issue p. eabf5759

15 March 2024 in Science Advances
Verified
Journal Article
Open access
ADAlessandro D’aMbrosio
Alessandro D’aMbrosio
DBDavide Bressan
Davide Bressan
EFElisa Ferracci
Elisa Ferracci
FCFrancesco Carbone
Francesco Carbone
PMPatrizia Mulè
Patrizia Mulè
FCFulvio Chiacchiera
Fulvio Chiacchiera
Oncogenic mutations accumulating in many chromatin-associated proteins have been identified in different tumor types. With a mutation rate from 10 to 57%, ARID1A has been widely considered a tumor suppressor gene. However, whether this role is mainly due to its transcriptional-related activities or its ability to preserve genome integrity is still a matter of intense debate. Here, we show that ARID1A is largely dispensable for preserving enhancer-dependent transcriptional regulation, being ARID1B sufficient and required to compensate for ARID1A loss. We provide in vivo evidence that ARID1A is mainly required to preserve genomic integrity in adult tissues. ARID1A loss primarily results in DNA damage accumulation, interferon type I response activation, and chronic inflammation leading to tumor formation. Our data suggest that in healthy tissues, the increased genomic instability that follows ARID1A mutations and the selective pressure imposed by the microenvironment might result in the emergence of aggressive, possibly immune-resistant, tumors.

16 April 2025 in The Laryngoscope
Verified
Journal Article
Open access
FPFrancesca Pirola
Francesca Pirola
EVElena Vezzoli
Elena Vezzoli
AFAndrea Falqui
Andrea Falqui
FGFrancesco Giombi
Francesco Giombi
Enrico HefflerEnrico Heffler
Enrico Heffler
Luca MalvezziLuca Malvezzi
Luca Malvezzi
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) often requires multiple treatments. When topical steroids prove insufficient, endoscopic sinus surgery (ESS) is the primary intervention. Among surgical options, reboot surgery is an innovative approach that offers the potential for prolonged disease control in rapidly recurring cases, delaying the need for monoclonal antibody (mAb) therapy. Our study investigates the histological and ultrastructural aspects of mucosal regeneration post‐reboot surgery, providing evidence beyond clinical observations.Methods: Five adult patients with recurrent CRSwNP, having undergone previous ESS, were enrolled in our study along with one control patient. All underwent partial reboot surgery, and biopsies were taken at pretreatment, 3‐, 12‐, and 24‐months post‐op. Analysis included clinical history, demographics, nasal polyps score, CT scans, and ACCESS score. All biopsies were analyzed using light (LM) and electron microscopy (both in transmission and scanning mode [TEM and SEM], respectively). Clinical response was assessed with Sinonasal Outcome Test‐22 (SNOT‐22) and Visual Analog Scale (VAS).Results: Difference of means of SNOT‐22 and VAS scores, pre versus at 24 months, were statistically significant (69.8 vs. 18.6, p = 0.043; 9.2 vs. 1.2, p = 0.038, respectively). The histological and ultrastructural analysis revealed significant changes in mucosal morphology, collagen composition, vascularity, and cell adhesion, with gradual restoration of normal epithelium and ciliary structure over time.Conclusion: Evidence of mucosal regeneration was provided at LM and electron microscopy. Reboot surgery is an innovative procedure that may be considered a valid alternative to mAbs, especially in younger patients, considering costs of medication and long‐term safety.Level of Evidence: Level 4.

25 March 2024 in Applied Nano
Verified
Journal Article
Open access
PDF file
MDMaria Paola Demichelis
Maria Paola Demichelis
APAgustina Mariana Portu
Agustina Mariana Portu
MGMario Alberto Gadan
Mario Alberto Gadan
AVAgostina Vitali
Agostina Vitali
VFValentina Forlingieri
Valentina Forlingieri
Umberto Anselmi-TamburiniUmberto Anselmi-Tamburini
Umberto Anselmi-Tamburini
Nanoparticles composed of inorganic boron-containing compounds represent a promising candidate as 10B carriers for BNCT. This study focuses on the synthesis, characterization, and assessment of the biological activity of composite nanomaterials based on boron carbide (B4C). Boron carbide is a compelling alternative to borated molecules due to its high volumetric B content, prolonged retention in biological systems, and low toxicity. These attributes lead to a substantial accumulation of B in tissues, eliminating the need for isotopically enriched compounds. In our approach, B4C nanoparticles were included in composite nanostructures with ultrasmall superparamagnetic nanoparticles (SPIONs), coated with poly (acrylic acid), and further functionalized with the fluorophore DiI. The successful internalization of these nanoparticles in HeLa cells was confirmed, and a significant uptake of 10B was observed. Micro-distribution studies were conducted using intracellular neutron autoradiography, providing valuable insights into the spatial distribution of the nanoparticles within cells. These findings strongly indicate that the developed nanomaterials hold significant promise as effective carriers for 10B in BNCT, showcasing their potential for advancing cancer treatment methodologies.

27 April 2026 in Clinical and Translational Allergy
Verified
Journal Article
Open access
FGFrancesco Giombi
Francesco Giombi
GPGian Marco Pace
Gian Marco Pace
EVElena Vezzoli
Elena Vezzoli
Fabio GrizziFabio Grizzi
Fabio Grizzi
FPFabio Pasqualini
Fabio Pasqualini
Luca MalvezziLuca Malvezzi
Luca Malvezzi
Background: As monoclonal antibodies have proven effective in managing recalcitrant chronic rhinosinusitis with nasal polyps (CRSwNP), the concept of disease remission is evolving, underscoring the need for a comprehensive, multimodal evaluation of disease burden over time. Objective: This study first presents ultrastructural changes of the nasal epithelium in patients treated with dupilumab, assessing the potential for mucosal regeneration during long‐term follow‐up. Methods: Ten patients ( n = 10) were enrolled. Baseline (T0) outcomes included Nasal Polyp Score, Lund‐Kennedy Score, 22‐item Sinonasal Outcome Test, Visual Analog Scale for nasal symptoms, and CT‐scan Lund‐Mackay Score. Mucosal samples were collected from the posteromedial aspect of prior antrostomies and analyzed using both light microscopy and transmission electron microscopy (TEM). Outcomes and mucosal sampling were reassessed at 12‐month (T1) and compared. Logistic bivariate analysis was performed to assess the relationship between ultrastructural tissue characteristics and clinical outcomes. Results: Significant improvements in all outcomes were observed at T1. A ciliated columnar epithelium was identifiable in most patients ( n = 7/10). Intercellular junctions, including desmosomes, tight and adherens junctions, were evident in half of the sample ( n = 5/10). Three patients ( n = 3/10) showed no evidence of epithelial regrowth. Endoscopic and radiologic outcomes were significantly linked to ultrastructural findings at T1. Higher eosinophilic infiltration at T0 was a positive predictor for the presence of pseudostratified epithelium at T1. Conclusions: These first preliminary data suggest that ultrastructural response is achievable in most patients with CRSwNP. Larger cohorts are required to strengthen these findings and support the concept of disease remission in course of mAb.

25 May 2026 in Journal of Hepatology
Verified
Journal Article
Open access
EBElena Barbon
Elena Barbon
CSChiara Simoni
Chiara Simoni
AAAmy Argabright
Amy Argabright
MBMolly Boettiger
Molly Boettiger
CNCamilla Negri
Camilla Negri
ACAlessio Cantore
Alessio Cantore
Isolated methylmalonic acidemia (MMA) is a severe inherited metabolic disorder caused by a deficiency of the mitochondrial enzyme methylmalonyl-CoA mutase, encoded by the MMUT gene. Lentiviral vector (LV)-based liver gene therapy may offer sustained therapeutic benefits even in pediatric patients, whose livers are still growing, due to the stable genomic integration of the therapeutic transgene. We evaluated the efficacy of liver-directed LV gene therapy in a mouse model of MMA and in patient-derived human fibroblasts. Systemic administration of an MMUT-expressing LV to 2-week-old MMA mice yielded a rapid, strong, and long-lasting (>1 year) therapeutic effect, with normalization of liver histology and mitochondrial ultrastructure. LV-mediated supraphysiological hepatic expression of MMUT promoted detoxification of the kidney and brain from methylmalonic acid and achieved broad correction of metabolomic, lipidomic, and proteomic profiles. Subsequently, we developed a codon-optimized MMUT transgene to increase expression and lower the minimal therapeutic dose. In 2-week-old MMA mice, this LV variant showed a dose-dependent improvement in metabolic biomarkers, clinical phenotype, and hepatocyte transduction efficiency (exceeding 80%). At the lower LV doses, corrected hepatocytes gained a selective proliferative advantage. Throughout all treated animals, LV integration site analysis revealed a high number of integrations without dominant clones, supporting a polyclonal profile. LV gene therapy provided metabolic improvement even in adult MMA mice, which had a more advanced disease stage than 2-week-old MMA mice. In vitro, LV delivery restored MMUT expression in patient-derived fibroblasts and partially corrected their metabolic abnormalities. These data provide preclinical proof-of-concept for the efficacy, safety, and extrahepatic therapeutic benefit of liver-directed LV gene therapy for MMA. Methylmalonic acidemia (MMA) is a severe metabolic disorder with few treatment options. A liver-targeted gene therapy using integrating lentiviral vectors (LV) could allow treatment of pediatric patients with a single dose, due to the stable integration of the therapeutic transgene into the DNA of target cells. In this study, we showed that in a relevant MMA mouse model, systemic LV administration led to long-lasting expression of the therapeutic enzyme in hepatocytes, which corrected metabolic abnormalities and significantly improved the disease phenotype. Supranormal enzyme levels in the liver enabled systemic detoxification and widespread metabolic normalization without detectable LV-related toxicity. We provide a detailed LV dose-response study evaluating the efficiency of gene transfer to hepatocytes and its therapeutic outcomes. Overall, these findings offer strong preclinical evidence to support progressing to clinical trials for MMA patients and help guide the potential use of liver-directed LV gene therapy for other inherited metabolic diseases.